Prognostic Significance of Blood Transfusion in Elderly Patients with Primary Diffuse Large B-Cell Lymphoma

Table 2

Univariate analysis of prognostic factors for survival time in elderly patients with primary DLBCL.

Characteristics			OS (mean)	Log-rank test		PFS (mean)	Log-rank test
Gender	Male	65	36.99	2.314	0.128	30.63	0.227	0.634
	Female	39	37.26			27.41
Ann Arbor staging	I-II	36	45.83	3.078	0.079	34.71	0.675	0.411
	III-IV	68	36.47			29.14
Extranodular involvement	Yes	41	38.71	0.555	0.456	30.26	0.274	0.601
	No	63	38.34			30.01
Bone marrow involvement	Yes	3	29.83	1.028	0.311	36.30	0.425	0.514
	No	101	18.71			30.97
B symptoms	Yes	13	23.37	3.105	0.078	15.95	5.052	0.025
	No	91	40.79			32.34
LDH (IU/L)	≥245	42	33.63	3.907	0.048	25.46	6.044	0.014
	<245	62	43.42			34.89
IPI	0–2	45	45.85	4.775	0.029	33.60	0.716	0.398
	3–5	59	35.43			29.46
Cell of origin	GCB	37	39.92	7.312	0.007	31.21	4.139	0.042
	Non-GCB	67	34.22			27.77
Plt	≥100 × 10^9/L	97	39.72	0.008	0.931	30.92	0.057	0.812
	<100 × 10^9/L	7	33.80			27.04
Hb (g/L)	≥100	85	40.61	0.993	0.319	32.10	1.906	0.167
	<100	19	30.96			22.75
Albumin (g/L)	≥35	67	43.85	5.822	0.016	33.32	3.498	0.061
	<35	37	32.61			26.81
Rituximab	Yes	70	43.32	5.087	0.004	33.78	3.638	0.056
	No	34	30.43			23.82
Blood transfusion	Yes	24	33.55	4.568	0.033	22.48	8.061	0.005
	No	80	41.53			33.65